title: [A case report of S-1 monotherapy for advanced hepatocellular carcinoma].
abstract: We describe our experience with a patient who had advanced hepatocellular carcinoma (HCC) that responded markedly to treatment with the oral fluoropyrimidine anticancer drug S-1 (120mg/day/body bid on day 1 through 28 followed by a 14-day recovery period). The patient was enrolled in a phase I / II study designed to evaluate the safety and efficacy of S-1 in patients with advanced HCC. The best overall efficacy was confirmed to be a partial response (PR). After a total of 6 courses of treatment given on an outpatient basis, the target lesion volume decreased by 73. 8%. With regard to adverse events, the patient did not develop Grade 3 or higher adverse drug reactions. Therefore, the patient continued outpatient treatment for a total of 6 courses. The duration of survival from the start of treatment until death was 820 days, suggesting that S-1 is moderately effective and well tolerated in patients with advanced HCC.
authors.affiliation: Dept. of Gastroenterology, Kanazawa University Hospital.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Yamashita
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Arai
authors.forename: Takeshi
authors.initials: T
authors.lastname: Terashima
authors.forename: Hajime
authors.initials: H
authors.lastname: Sunagozaka
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Shimakami
authors.forename: Taro
authors.initials: T
authors.lastname: Yamashita
authors.forename: Eishiro
authors.initials: E
authors.lastname: Mizukoshi
authors.forename: Akito
authors.initials: A
authors.lastname: Sakai
authors.forename: Masao
authors.initials: M
authors.lastname: Honda
authors.forename: Shuichi
authors.initials: S
authors.lastname: Kaneko
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D004338:Drug Combinations; D017809:Fatal Outcome; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000627:therapeutic use*; D005641:Tegafur / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid